Testing tocilizumab plus atezolizumab after lung cancer treatment failure
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) with advanced non-squamous non-small cell lung cancer (stage IV or it came back after a prior cure attempt).
- Your cancer has already been treated with at least one full round of therapy before joining the study.
- You must have taken an immune checkpoint inhibitor right before this trial (the most recent treatment that did not work).
- Your day-to-day functioning is fairly good (ECOG performance status 0–2).
- You do not have a gene driver mutation that could be treated with targeted drugs.
- You do not have certain serious problems after prior immunotherapy (no toxicity higher than grade 3 from the last immune treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
This trial is testing a combination of two drugs, cabozantinib and atezolizumab, for people with advanced lung cancer that has low PD-L1 levels. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
This study tests whether adding a type of chemotherapy called platinum-based chemo to an immunotherapy drug called tislelizumab helps people with advanced non-small cell lung cancer that has spread and has high PD-L1. The trial aims to see if this combination works better than immunotherapy alone in people with larger tumors.
Hear when a new Lung Cancer, Nonsmall Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.